Related Experiment Videos
Autoimmune haemolytic anaemia in a newborn infant
M Motta1, A Cavazza, C Migliori
1Division of Neonatology and Neonatal Intensive Care, Spedali Civili, Brescia, Italy.
Insights
This case study details an infant with perinatal autoimmune hemolytic anemia. Combined steroid and cyclosporin treatment effectively managed the condition, leading to a healthy outcome.
Area of Science:
- Pediatrics
- Immunology
- Hematology
Background:
- Autoimmune hemolytic anemia (AIHA) is a rare condition.
- Perinatal onset AIHA presents unique diagnostic and therapeutic challenges.
- High transfusion requirements can complicate management in infants.
Observation:
- An infant presented with autoimmune hemolytic anemia shortly after birth.
- The infant required frequent blood transfusions due to severe hemolysis.
- Initial treatments were insufficient to control the condition.
Findings:
- Combined therapy with corticosteroids and cyclosporine was initiated.
- This combined immunosuppressive treatment successfully reduced hemolysis.
- Transfusion needs significantly decreased following the combined therapy.
Implications:
- Early and aggressive immunosuppressive therapy can be effective in managing severe perinatal AIHA.
- Combined steroid and cyclosporine treatment offers a viable therapeutic option.
- Successful management can lead to long-term positive outcomes for affected infants.
Abstract:
The case is reported of an infant with autoimmune haemolytic anaemia of perinatal onset. Combined treatment with steroids and cyclosporin was necessary to improve haemolysis and reduce the high transfusion requirements. Treatment was discontinued at 13 months of age. The child was healthy at the follow up at 24 and 36 months of age.